PreOmics Exit

PreOmics develops and provides innovative technologies for customers around the world for mass spectrometry (MS) - based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.

Press releases

Press
preomics logo
18. January 2022

PreOmics Announces Early Investors’ Exit and Closing of Series B Financing to Accelerate R&D and Commercialization of Proteomics Tools and Consumables

PreOmics Offers Unique Technologies, Advanced Automation Solutions and High-Performance Consumables for the Homogenization, Enrichment and Proteomic Sample Preparation of Biopsy, Tissue, Cell Line and Plasma Samples in Unbiased, Deep Proteomics for Pharmaceutical and Clinical Research MUNICH, Germany – January 18, 2022 – PreOmics GmbH, a Martinsried, Germany-based developer of innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis
 
Press
18. December 2018
High-Tech Gründerfonds and Think.Health Ventures together with Business Angels invest 3.3 million euros in a series A for the growth of PreOmics in Martinsried, Germany
PreOmics develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry. Today, the processing of samples for mass spectrometry is usually carried out according to homemade protocols. These processes are slow, not reproducible, not robust and cannot be automated. These solutions are therefore very time-consuming and costly, which can lead to the loss of valuable samples. PreOmics addresses these problems with a standardized technology that enables robust
 

Info & Contact

Garwin Pichler
Web:
preomics.com

Address

PreOmics GmbH
Am Klopferspitz 19
D-82152 Planegg/Martinsried

In portfolio

06. Feb 2017 – 18. Jan 2022

Sector

HTGF Manager

 
Dr. Fabian Mohr, Senior Investment Manager
Exit